Skip to contentpdufa.bio

volixibat VANTAGE

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

volixibat VANTAGE is a Mirum Pharmaceuticals, Inc. program in cholestatic pruritus in primary biliary cholangitis (PBC). Its next catalyst is a Readout in Q1 2027.

MIRM catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Cholestatic pruritus in primary biliary cholangitis (PBC). Sponsor: Mirum Pharmaceuticals, Inc. (MIRM). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027MIRM

Specialist biotech funds holding MIRM, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Baker Bros. Advisors445,975$38.1 millionfiled November 16, 2026
BVF Inc.407,226$34.8 millionfiled November 16, 2026
RA Capital Management159,278$13.6 millionfiled November 16, 2026
Perceptive Advisors115,391$9.9 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is volixibat VANTAGE's next FDA decision or readout?

The next tracked catalyst for volixibat VANTAGE is a Readout in Q1 2027.

What happened at volixibat VANTAGE's most recent FDA decision?

No FDA decision for volixibat VANTAGE is in our archive yet.

What is volixibat VANTAGE used for?

In our records volixibat VANTAGE is under review or in development for Cholestatic pruritus in primary biliary cholangitis (PBC).

Who makes volixibat VANTAGE?

Mirum Pharmaceuticals, Inc. (MIRM).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.